Strong Multinational Growth Performance Despite Economic Slowdown


BMI View: In line with our optimism towards the Chinese healthcare sector, many multinational pharmaceutical firms continue to record healthy double-digit revenue growth in Q114, despite the economic slowdown. Given the attractiveness of the Chinese pharmaceutical market (due to its ageing population, increasingly personal wealth and government support for healthcare), we expect continued investments from foreign investors into the pharmaceutical and healthcare sector.

The majority of multinational pharmaceutical firms that have disclosed their sales figures in China in Q114 achieved strong double digit growth, in line with our long-term optimism towards the Chinese pharmaceutical and healthcare sector.

AstraZeneca

Mixed Performance
Revenues Generated In China By Selected Multinational Pharmaceutical Firms (USDmn)

or Register now for free to read the full article

This article is tagged to:
Related sectors of this article: Pharmaceuticals & Healthcare
Geography: China

Access all of our latest analysis, data and forecasts - request a trial